2023
End-of-Life Systemic Oncologic Treatment in the Immunotherapy Era: The Role of Race, Insurance, and Practice Setting
Canavan M, Wang X, Ascha M, Miksad R, Showalter T, Calip G, Gross C, Adelson K. End-of-Life Systemic Oncologic Treatment in the Immunotherapy Era: The Role of Race, Insurance, and Practice Setting. Journal Of Clinical Oncology 2023, 41: 4729-4738. PMID: 37339389, PMCID: PMC10602547, DOI: 10.1200/jco.22.02180.Peer-Reviewed Original ResearchConceptsSystemic treatmentEnd of lifeWhite patientsBlack patientsOdds ratioLarge real-world populationPractice settingsTreatment ratesPatient-level factorsEmergency department useIntensive care unitReal-world populationDay of deathImmunotherapy eraSystemic therapyOncologic treatmentCare unitDeidentified databaseDepartment usePatient raceInsurance typeMetastatic cancerDownstream careMedicaid patientsHigher odds
2019
Effects of rising drug costs on efforts to control overall cost at a large academic cancer center.
Adelson K, Canavan M, Supalla S, Sedghi T, Chaudhry B, Sinanis N, Gross C. Effects of rising drug costs on efforts to control overall cost at a large academic cancer center. Journal Of Clinical Oncology 2019, 37: 2-2. DOI: 10.1200/jco.2019.37.27_suppl.2.Peer-Reviewed Original ResearchOncology Care ModelLarge academic cancer centerAcute care useAcademic cancer centerPost-acute careMean costCancer CenterCare useDrug costsEmergency department useCost of hospitalizationMean total costValue-based payment programsCost of pharmaceuticalsCancer HospitalCancer careDepartment useTotal episodesInpatient careMedicare claimsCare modelCareEpisodesUtilization categoriesPharmaceutical spending